Liposomal doxorubicin (Myocet™) and conventional anthracyclines: A comparison

Breast

Volumn 10, Issue SUPPL. 2, 2001, Pages 28-33

  Marty, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; LIPOSOME;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; TIME; TREATMENT FAILURE;

EID: 0034986609     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2000.0174     Document Type: Article

References (24)

1. Treatment of breast cancer
2. Current and potential chemotherapeutic agents used for induction therapy in the treatment of breast cancer
3. Cardiotoxicity of doxorubicin and other anthracycline derivatives
4. Risk factors for doxorubicin-induced congestive heart failure
5. Liposomal doxorubicin
6. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial
7. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
8. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
9. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
10. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated doxorubicin
11. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
12. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter cancer
13. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues
14. Might adriamycinol contribute to adriamycin-induced cardiotoxicity
15. Doxorubicin cardiotoxicity may be caused by its metabolite doxorubicinol
16. 2: Evidence for enhanced toxicity with multiagent chemotherapy
17. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumour response
18. Effect of anthracycline antibiotics on oxygen radical formation in rat heart
19. Adriamycin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity
20. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer
21. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
22. Epirubicin: A review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer
23. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer
24. Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients